Pharmaceutical Technology on MSN21h
Health Canada approves Biogen’s Skyclarys for Friedreich’s ataxia
Health Canada has granted approval for Biogen’s Skyclarys (omaveloxolone) to treat Friedreich’s ataxia (FA), a rare, ...
The Sun Times News4d
Chelsea Hosts Families for Friedreich’s Ataxia Foundation Fundraiser
The Families for Friedreich’s Ataxia Foundation is grateful for the incredible support from Chelsea and the surrounding ...
Healio11d
VIDEO: Omaveloxolone improves neurologic function in Friedreich’s ataxia patients
Careful monitoring of neurologic function, cardiac function, presence of diabetes, monitoring for scoliosis and visual loss ...
PTC Therapeutics: Upside In Rare Disease Innovation
PTC Therapeutics could boost revenue with vatiquinone for Friedreich's ataxia. Find out why PTCT stock is poised for growth ...
Medindia1d
SKYCLARYS (omaveloxolone) Approval by Health Canada Ushers in a New Era for Friedreich's Ataxia Treatment in Canada
As the only approved treatment to address disease progression, SKYCLARYS addresses a long-standing gap in the care of Canadians living with Friedreich's ataxia Friedreich's ...
PharmaTimes6d
Minoryx doses first patient with leriglitazone in Rett syndrome study
Minoryx Therapeutics has dosed the first patient in its phase 2a TREE study, which evaluates the safety and efficacy of ...
Design Therapeutics provides corporate highlights, anticipated milestones
Design has initiated dosing in a Phase 1 clinical trial in healthy volunteers in Australia to evaluate the safety and ...
Biogen Inc. (BIIB) Management presents at Leerink Global Healthcare Conference 2025 (Transcript)
Leerink Global Healthcare Conference 2025 March 10, 2025 11:20 AM ETCompany ParticipantsAlisha Alaimo - President of ...
Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial Results
Initiated Phase 1 Single Ascending Dose Trial of DT-216P2 in Healthy Volunteers; Friedreich Ataxia (FA) Patient Dosing to Begin in mid-2025Dosing ...